U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars …

In (>5%) of patients with: Postmenopausal osteoporosis were back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.
Source: back pain